<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20231113193811&amp;v=2.17.9.post6+ 86 293ac&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC -<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;ff=20231113193811&amp;v=2.17.9.post6+86293ac&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 11 月 14 日星期二 00:38:11 +0000</lastbuilddate><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><ttl> 120</ttl><item><title>长房性高频率发作≥24小时的患者使用艾多沙班抗凝</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956458/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>结论：这项假设生成分析并未发现设备检测到 AHRE 和中风危险因素的患者中 AHRE 持续时间与抗凝治疗之间存在相互作用。需要进一步研究来识别具有高中风风险的长 AHRE 患者。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 11 月 12 日：ehad771。doi：10.1093/eurheartj/ehad771。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：长期心房高频率发作（AHRE）≥24小时且有卒中危险因素的患者通常接受抗凝治疗以预防卒中。从未将这些患者的抗凝治疗与不抗凝治疗进行比较。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：NOAH-AFNET 6 的二次预先指定分析检查了 AHRE 患者基线 AHRE 持续时间与艾多沙班抗凝治疗与安慰剂相比的相互作用以及中风危险因素。主要疗效结局是中风、全身性栓塞或心血管死亡的综合结果安全性结局是大出血和死亡的综合结果。关键的次要结局是这些结局和心电图诊断的房颤的组成部分。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：入组 NOAH-AFNET 6 的 259/2389 名患者（11%，78 ± 7 岁，28% 女性，CHA2DS2-VASc 评分 4）在基线时存在 AHRE ≥24 小时。临床特征与患有以下疾病的患者没有不同：较短的 AHRE。在 1.8 年的中位随访期间，主要结局发生在接受抗凝治疗的 9/132 名 AHRE ≥24 小时的患者（4.3%/患者年，2 次中风）和 14/127 名接受安慰剂治疗的患者中。 （6.9%/患者年，2 次中风）。AHRE 持续时间与抗凝治疗的疗效（p 相互作用 = 0.65）或安全性（p 相互作用 = 0.98）没有相互作用。包括 AHRE 作为连续参数的分析证实了这一点。患者AHRE ≥24 小时的患者比 AHRE 较短的患者（8.2%/患者年；p &lt; 0.001）发生更多心电图诊断的房颤（17.0%/患者年）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：这项假设生成分析并未发现设备检测到 AHRE 和中风危险因素的患者中 AHRE 持续时间与抗凝治疗之间存在相互作用。需要进一步研究来识别具有高中风风险的长 AHRE 患者。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956458/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37956458</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad771>10.1093/eurheartj/ehad771</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956458</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>尼娜·贝歇尔</dc:creator><dc:creator>托比亚斯·托尼斯</dc:creator><dc:creator>埃马努埃莱·贝尔塔利亚</dc:creator><dc:creator>卡琳娜·布洛姆斯特罗姆-伦奎斯特</dc:creator><dc:creator>阿克塞尔·布兰德斯</dc:creator><dc:creator>努诺·卡巴内拉斯</dc:creator><dc:creator>梅兰妮·卡尔弗特</dc:creator><dc:creator>约翰·卡姆</dc:creator><dc:creator>格雷戈里·克卢韦拉基斯</dc:creator><dc:creator>格奥尔基·安德烈·丹</dc:creator><dc:creator>沃尔夫冈·迪希特尔</dc:creator><dc:creator>汉斯·克里斯托夫·迪纳</dc:creator><dc:creator>亚历山大·费伦茨</dc:creator><dc:creator>安德烈亚斯·戈特</dc:creator><dc:creator>乔里斯·R·德·格鲁特</dc:creator><dc:creator>阿斯特丽德·赫尔曼斯</dc:creator><dc:creator>格雷戈里·YH·利普</dc:creator><dc:creator>安德烈·卢宾斯基</dc:creator><dc:creator>埃洛伊·马里琼</dc:creator><dc:creator>贝拉·默克利</dc:creator><dc:creator>路易斯·蒙</dc:creator><dc:creator>安-凯瑟琳·奥兹加</dc:creator><dc:creator>金·拉贾潘</dc:creator><dc:creator>安德烈·萨科齐</dc:creator><dc:creator>丹尼尔·谢尔</dc:creator><dc:creator>雷纳特·B·施纳贝尔</dc:creator><dc:creator>乌尔里希·肖顿</dc:creator><dc:creator>苏珊·塞纳</dc:creator><dc:creator>伊曼纽尔·西曼蒂拉基斯</dc:creator><dc:creator>帕诺斯·瓦尔达斯</dc:creator><dc:creator>瓦西尔·维尔切夫</dc:creator><dc:creator>丹·威克特尔</dc:creator><dc:creator>安东尼娅·扎普夫</dc:creator><dc:creator>保卢斯·基希霍夫</dc:creator><dc:date>2023-11-13</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>长房性高频率发作≥24小时的患者使用艾多沙班抗凝</dc:title><dc:identifier>下午:37956458</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad771</dc:identifier></item><item><title>更正：2020 ACC/AHA 瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956227/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通量</b>。2023 年 11 月 14 日；148(20):e185。doi:10.1161/CIR.0000000000001190。Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956227/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37956227</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001190>10.1161/CIR.0000000000001190</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956227</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:date> 2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>更正：2020 ACC/AHA 瓣膜性心脏病患者管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会的报告</dc:title><dc:identifier>下午:37956227</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001190</dc:identifier></item><item><title>布鲁格达综合症的风险分层：我们能降到多低？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37956226/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 14 日；148(20):1556-1558.doi: 10.1161/CIRCULATIONAHA.123.066697.Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956226/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37956226</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066697>10.1161/CIRCULATIONAHA.123.066697</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956226</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>阿瑟·A·M·王尔德</dc:creator><dc:creator>约翰·赛南</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>布鲁格达综合症的风险分层：我们能降到多低？</dc:title><dc:identifier>下午:37956226</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066697</dc:identifier></item><item><title>张等人关于文章“多梳蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信函</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956225/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 14 日；148(20):1602-1603. doi: 10.1161/CIRCULATIONAHA.123.066427. Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956225/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37956225</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066427>10.1161/CIRCULATIONAHA.123.066427</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956225</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>张曼如</dc:creator><dc:creator>郭丹丹</dc:creator><dc:creator>赵晶</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>张等人关于文章“多梳蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信函</dc:title><dc:identifier>下午:37956225</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066427</dc:identifier></item><item><title> Cho 和 Yoon 对有关文章“Polycomb 组蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信件的回应</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956224/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 14 日；148(20):1604-1605。doi: 10.1161/CIRCULATIONAHA.123.066624。Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956224/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37956224</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066624>10.1161/CIRCULATIONAHA.123.066624</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956224</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>曹圭元</dc:creator><dc:creator>尹英燮</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>Cho 和 Yoon 对有关文章“Polycomb 组蛋白 CBX7 通过调节 TARDBP/RBM38 轴抑制心肌细胞增殖”的信件的回应</dc:title><dc:identifier>下午:37956224</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.066624</dc:identifier></item><item><title>使用患者来源的诱导多能干细胞研究由 &lt;em>;NAA10&lt;/em>; 遗传变异引起的长 QT 综合征</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956223/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 14 日；148(20):1598-1601.doi: 10.1161/CIRCULATIONAHA.122.061864.Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956223/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37956223</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.122.061864>10.1161 / CIRCULATIONAHA.122.061864</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956223</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>纳吉特·贝尔巴奇尔</dc:creator><dc:creator>吴一阳</dc:creator><dc:creator>沉梦成</dc:creator><dc:creator>张索菲亚·L</dc:creator><dc:creator>张乔</dc:creator><dc:creator>刘春</dc:creator><dc:creator>比约恩·C·诺尔曼</dc:creator><dc:creator>戈尔森·里昂</dc:creator><dc:creator>马宁</dc:creator><dc:creator>约瑟夫·吴</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>使用患者来源的诱导多能干细胞研究由 &lt;em>;NAA10&lt;/em>; 遗传变异引起的长 QT 综合征</dc:title><dc:identifier>下午:37956223</dc:identifier><dc:identifier> doi:10.1161/循环AHA.122.061864</dc:identifier></item><item><title> &lt;em>;流通&lt;/em>;系列期刊的亮点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956222/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>. 2023 年 11 月 14 日；148(20):1593-1597. doi: 10.1161/CIRCULATIONAHA.123.067572. Epub 2023 年 11 月 13 日。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956222/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37956222</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067572>10.1161/循环AHA.123.067572</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956222</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:date> 2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>&lt;em>;流通&lt;/em>;系列期刊的亮点</dc:title><dc:identifier>下午:37956222</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067572</dc:identifier></item><item><title>艾多沙班治疗慢性血栓栓塞性肺动脉高压患者的多中心、单盲、随机、华法林对照试验：KABUKI 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37956127/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 13 日。doi：10.1161/CIRCULATIONAHA.123.067528。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37956127/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37956127</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067528>10.1161/CIRCULATIONAHA.123.067528</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37956127</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>细川一也</dc:creator><dc:creator>渡边弘子</dc:creator><dc:creator>谷口佑</dc:creator><dc:creator>池田信隆</dc:creator><dc:creator>稻波匠美</dc:creator><dc:creator>安田聪</dc:creator><dc:creator>室原丰明</dc:creator><dc:creator>波多野胜</dc:creator><dc:creator>田村雄一</dc:creator><dc:creator>山下淳</dc:creator><dc:creator>辰巳光一郎</dc:creator><dc:creator>辻野一三</dc:creator><dc:creator>小早川优子</dc:creator><dc:creator>安达四郎</dc:creator><dc:creator>矢板信宏</dc:creator><dc:creator>水月俊</dc:creator><dc:creator>户高浩二</dc:creator><dc:creator>福田敬一</dc:creator><dc:creator>筒井宏之</dc:creator><dc:creator>阿部光太郎</dc:creator><dc:creator>歌舞伎调查员</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>艾多沙班治疗慢性血栓栓塞性肺动脉高压患者的多中心、单盲、随机、华法林对照试验：KABUKI 试验</dc:title><dc:identifier>下午：37956127</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067528</dc:identifier></item><item><title>托塞米与呋塞米在新发慢性心力衰竭患者与恶化慢性心力衰竭患者中的​​比较：TRANSFORM-HF 随机临床试验的子研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在因 HF 住院后出院的患者中，与 WHF 相比，新发 HF 具有更好的临床和患者报告结果。无论 HF 类型如何，托拉塞米和呋塞米在 12 个月内没有显着差异临床或患者报告的结果。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol.2023 年 11 月 13 日。doi：10.1001/jamacardio.2023.4776。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：新发心力衰竭 (HF) 和慢性心力衰竭 (WHF) 恶化患者之间的临床特征、结局和利尿治疗效果可能存在差异。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：比较托拉塞米与呋塞米在因新发心衰与 WHF 住院患者中的临床特征和治疗结果。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：在托塞米与呋塞米治疗心力衰竭的比较 (TRANSFORM-HF) 试验中随机分配的所有具有射血分数的患者均纳入本事后分析，该试验于 6 月 18 日至 2022 年 3 月进行。研究数据是在 2023 年 3 月至 5 月期间进行分析的。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：患者根据心力衰竭类型进行分类，并根据袢利尿策略进一步分类。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：终点包括 12 个月内的全因死亡率和住院结果，以及堪萨斯城心肌病问卷临床总结评分 (KCCQ-CSS) 相对于基线的变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在 2858 名患者（平均 [SD] 年龄，64.5 [14.0] 岁；1803 名男性 [63.1%]）中，838 名患者 (29.3%) 患有新发 HF，2020 名患者 (70.7%) 患有 WHF。更年轻（平均 [SD] 年龄，60.6 [14.5] 岁 vs 66.1 [13.5] 岁），肾小球滤过率较高（平均 [SD]，68.6 [24.9] vs 57.0 [24.0]），钠尿肽水平较低（中位[IQR]，脑型利钠肽，855.0 [423.0-1555.0] pg/mL vs 1022.0 [500.0-1927.0] pg/mL），并且倾向于使用较低剂量的袢利尿剂出院（平均[SD]，50.3） [46.2] mg vs 63.8 [52.4] mg）。从头心力衰竭与 12 个月时较低的全因死亡率相关（从头心力衰竭，838 例中的 65 例 [9.1%] 对比 WHF，2020 年的 408 例 [25.4%]；调整后的风险比率 [aHR]，0.50；95% CI，0.38-0.66；P &lt; .001)。同样，在患有 de 疾病的患者中，12 个月时全因首次再住院率较低，12 个月时 KCCQ-CSS 较基线有较大改善。 novo HF（中位数 [IQR]：de novo，29.94 [27.35-32.54] vs WHF，23.68 [21.62-25.74]；调整后的平均值估计差异：6.26；95% CI，3.72-8.81；P &lt; .001）。托拉塞米与呋塞米两种治疗的死亡率均无显着差异（事件数[每 100 名患者年发生率]：托拉塞米，27 例 [7.4%] 对比呋塞米，38 例 [10.9%]；aHR，0.70；95% CI，0.40-1.14；P = .15）或 WHF（托塞米 212 [26.8%] 与呋塞米，196 [24.0%]；aHR，1.08；95% CI，0.89-1.32；P = .42；交互作用 P = .10)，此外，在新发 HF 或 WHF 中，托拉塞米与呋塞米策略在住院治疗、首次全因住院治疗或 12 个月总住院治疗方面没有显着差异。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在因 HF 住院后出院的患者中，与 WHF 相比，新发 HF 具有更好的临床和患者报告结果。无论 HF 类型如何，托拉塞米和呋塞米在 12 个月内没有显着差异临床或患者报告的结果。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37955908/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37955908</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.4776>10.1001/jamacardio.2023.4776</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955908</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>塞利姆·克里姆</dc:creator><dc:creator>森希尔·阿南德</dc:creator><dc:creator>斯蒂芬·J·格林</dc:creator><dc:creator>陈安琪</dc:creator><dc:creator>丹尼尔·沃伊迪拉</dc:creator><dc:creator>胡安·维拉罗</dc:creator><dc:creator>赫伯特·霍特</dc:creator><dc:creator>约翰·M·赫尔</dc:creator><dc:creator>埃里克·爱森斯坦</dc:creator><dc:creator>凯文·J·安斯特罗姆</dc:creator><dc:creator>伯特伦·皮特</dc:creator><dc:creator>埃里克·委拉斯开兹</dc:creator><dc:creator>罗伯特·J·门茨</dc:creator><dc:date>2023-11-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>托塞米与呋塞米在新发慢性心力衰竭患者与恶化慢性心力衰竭患者中的​​比较：TRANSFORM-HF 随机临床试验的子研究</dc:title><dc:identifier>下午:37955908</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4776</dc:identifier></item><item><title>美国的社区环境负担和心血管健康</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955891/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>结论和相关性：在这项针对美国社区的横断面研究中，累积的环境负担与较高的心血管危险因素和疾病发生率相关，尽管绝对差异很小。在社会弱势社区中观察到最强的关联。环境条件将改善心血管健康需要更多的前瞻性研究。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 11 月 13 日。doi：10.1001/jamacardio.2023.4680。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：心血管疾病是美国的首要死因。然而，人们对美国社区累积环境负担与心血管健康之间的关系知之甚少。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：评估社区环境负担与心血管危险因素和疾病患病率的总体关系以及社会脆弱性水平的关系。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、设置和参与者：这是一项针对 71 659 个美国人口普查区的全国横断面研究。环境负担 (EBI) 和社会脆弱性指数来自美国疾病控制和预防中心 (CDC) 以及有毒物质和疾病机构登记系统与 2020 年 CDC PLACES 数据集相关联。数据分析时间为 2023 年 3 月至 10 月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：EBI，衡量累积环境负担的指标，涵盖 5 个领域（空气污染、危险或有毒场所、建筑环境、交通基础设施和水污染）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">主要结果和指标：心血管危险因素（高血压、糖尿病和肥胖）和心血管疾病（冠心病和中风）的社区患病率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：在美国各地，环境负担最高的社区（EBI 顶部四分位数）比环境负担最低的社区（EBI 底部四分位数）更有可能位于城市（16 626 [92.7%] vs 13 414 [75.4%]）中西部地区（5191 [28.9%] vs 2782 [15.6%]）的社会脆弱性得分中位数（IQR）较高（0.64 [0.36-0.85] vs 0.42 [0.20-0.65]），并且成年人的比例较高种族或族裔群体（中位数 [IQR]，34% [12-73] vs 12% [5-30]）。调整后，环境负担最高的社区的心血管危险因素发生率显着高于环境负担最低的社区负担，包括高血压（平均 [SD]，32.83% [7.99] vs 32.14% [6.99]；调整后差异，0.84%；95% CI，0.71-0.98）、糖尿病（平均 [SD]，12.19% [4.33] vs 10.68% [3.27]；调整后差异，0.62%；95% CI，0.53-0.70）和肥胖（平均值 [SD]，33.57% [7.62] vs 30.86% [6.15]；调整后差异，0.77%；95% CI ，0.60-0.94）。同样，环境负担最高的社区冠心病发病率也显着较高（平均值 [SD]，6.66% [2.15] vs 6.82% [2.41]；调整后差异，0.28%；95% CI， 0.22-0.33）和中风（平均值 [SD]，3.65% [1.47] vs 3.31% [1.12]；调整后差异，0.19%；95% CI，0.15-0.22）。在匹配环境负担最高和最低的社区后，结果一致环境负担四分位数与心血管危险因素和疾病之间的关联在弱势社会社区中最为明显。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论和相关性：在这项针对美国社区的横断面研究中，累积的环境负担与较高的心血管危险因素和疾病发生率相关，尽管绝对差异很小。在社会弱势社区中观察到最强的关联。环境条件将改善心血管健康需要更多的前瞻性研究。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37955891/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37955891</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.4680>10.1001/jamacardio.2023.4680</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955891</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>迈克尔·刘</dc:creator><dc:creator>维沙尔·R·帕特尔</dc:creator><dc:creator>蕾妮·萨拉斯</dc:creator><dc:creator>玛丽·B·赖斯</dc:creator><dc:creator>德鲁夫·卡齐</dc:creator><dc:creator>赵年政</dc:creator><dc:creator>里希·K·瓦德拉</dc:creator><dc:date>2023-11-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>美国的社区环境负担和心血管健康</dc:title><dc:identifier>下午:37955891</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4680</dc:identifier></item><item><title>优先考虑暴露组以减轻心血管疾病负担</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955872/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol.2023 年 11 月 13 日。doi：10.1001/jamacardio.2023.4722。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37955872/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37955872</a> | DOI： <a href=https://doi.org/10.1001/jamacardio.2023.4722>10.1001/jamacardio.2023.4722</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955872</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>艾丽卡·S·斯帕茨</dc:creator><dc:creator>陈凯</dc:creator><dc:creator>哈伦·M·克鲁霍尔兹</dc:creator><dc:date>2023-11-13</dc:date><dc:source>美国医学会杂志心脏病学</dc:source><dc:title>优先考虑暴露组以减轻心血管疾病负担</dc:title><dc:identifier>下午：37955872</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4722</dc:identifier></item><item><title>射血分数降低的心力衰竭患者的体力活动：增加容量</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955620/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 13 日。doi：10.1161/CIRCULATIONAHA.123.067588。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37955620/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37955620</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067588>10.1161/循环AHA.123.067588</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955620</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>大卫·J·惠兰</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>射血分数降低的心力衰竭患者的体力活动：增加容量</dc:title><dc:identifier>下午:37955620</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067588</dc:identifier></item><item><title>对射血分数降低的心力衰竭患者进行生活方式步行干预：WATCHFUL 试验</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>背景：体力活动对于射血分数降低的心力衰竭 (HFrEF) 至关重要，而将步行融入日常生活是管理此类体力活动的特别合适的形式。本研究旨在确定为期 6 个月的生活方式步行干预是否结合自我锻炼与常规护理相比，监测和定期电话咨询可提高稳定的 HFrEF 患者通过六分钟步行测试 (6MWT) 评估的功能能力。方法：WATCHFUL 试验是... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 13 日。doi：10.1161/CIRCULATIONAHA.123.067395。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>体力活动对于射血分数降低的心力衰竭 (HFrEF) 至关重要，而将步行融入日常生活是管理此类体力活动的特别合适的形式。本研究旨在确定为期 6 个月的生活方式步行干预是否结合自我锻炼与常规护理相比，监测和定期电话咨询可改善稳定的 HFrEF 患者通过六分钟步行测试 (6MWT) 评估的功能能力。<b>方法：</b> WATCHFUL 试验是一项为期 6 个月、多中心、平行组、随机对照试验从捷克六个心血管中心招募 HFrEF 患者。符合资格的参与者年龄≥18 岁，左心室射血分数 &lt;40%，有 NYHA II/III 级症状，正在接受指南推荐的药物治疗，不包括基线 6MWT 超过 450m 的患者。干预组配备了 Garmin vívofit 活动追踪器，并每月接受研究护士的电话咨询，鼓励他们采用自我监控、目标设定和行动计划等行为改变技术来增加每日步数。继续常规护理。主要结果是 6 个月时 6MWT 期间各组行走距离（以米为单位）的差异。次要结果包括每日步数和中度至剧烈体力活动分钟数 (MVPA)（通过髋部佩戴的 Actigraph wGT3X-BT 加速度计、NT-proBNP 和 hsCRP 生物标志物、射血分数、人体测量指标、抑郁评分、自我效能、生活质量和生存风险评分。主要分析是按意向治疗进行的。<b>结果：</b>从 218 名筛查患者中，202 名患者被随机分配（65 岁；22.8% 女性；90.6% NYHA II；左心室射血分数 32.5%；6MWT 385m；每天 5071 步；每天 10.9 分钟 MVPA）。六个月时， 6MWT 未检测到组间差异（7.4 m，95% CI -8.0 至 22.7，p=0.345，N=186）。干预组将平均每日步数增加了 1420（95% CI：749；2091） ) 和每日 MVPA 分钟数比对照组提高 8.2 (95% CI: 3.0; 13.3)。没有检测到任何其他次要结局的组间差异。<b>结论：</b>虽然 HFrEF 患者的生活方式干预将每日步数改善了约25% 的人未能表现出功能能力的相应改善。需要进一步研究来了解增加体力活动与功能结果之间的脱节。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37955615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37955615</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067395>10.1161/CIRCULATIONAHA.123.067395</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955615</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>托马斯·维特洛夫斯基</dc:creator><dc:creator>米哈尔·西拉内克</dc:creator><dc:creator>特蕾莎·弗莱博娃</dc:creator><dc:creator>尤利安·甘特</dc:creator><dc:creator>伊维塔·斯沃博多娃</dc:creator><dc:creator>阿莱斯·林哈特</dc:creator><dc:creator>伊里·帕雷尼察</dc:creator><dc:creator>玛丽·米克利科娃</dc:creator><dc:creator>伦卡·苏亚科娃</dc:creator><dc:creator>大卫·波斯皮希尔</dc:creator><dc:creator>拉德克·佩卢什</dc:creator><dc:creator>丹妮拉·奥德拉兹科娃</dc:creator><dc:creator>彼得·帕里泽克</dc:creator><dc:creator>简·普雷切克</dc:creator><dc:creator>马丁·胡提拉</dc:creator><dc:creator>米洛斯·塔博斯基</dc:creator><dc:creator>吉里·维斯利</dc:creator><dc:creator>马丁·格里瓦</dc:creator><dc:creator>米罗斯拉夫·塞梅拉德</dc:creator><dc:creator>瓦茨拉夫邦克</dc:creator><dc:creator>卡罗琳娜·赫拉布科娃</dc:creator><dc:creator>阿德拉·沃伊库夫科娃</dc:creator><dc:creator>米哈尔·斯沃博达</dc:creator><dc:creator>扬·贝洛拉维克</dc:creator><dc:creator>警惕的调查人员</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>对射血分数降低的心力衰竭患者进行生活方式步行干预：WATCHFUL 试验</dc:title><dc:identifier>下午:37955615</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067395</dc:identifier></item><item><title>美国大学体育协会运动员的心脏性猝死：一项为期 20 年的研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>背景：了解年轻竞技运动员心源性猝死 (SCD) 的发病率、原因和趋势对于制定预防政策至关重要。方法：这项研究包括美国大学体育协会运动员在 20 年时间范围内的死亡情况（2017 年 7 月 1 日） 2002 年至 2022 年 6 月 30 日）。通过 4 个独立的数据库和搜索策略（国家大学体育协会决议列表、家长心脏观察数据库……）确定运动员死亡情况。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 13 日。doi：10.1161/CIRCULATIONAHA.123.065908。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>背景：</b>了解年轻竞技运动员心源性猝死 (SCD) 的发病率、原因和趋势对于制定预防政策至关重要。<b>方法：</b>这项研究包括美国大学体育协会运动员在 20 年时间范围内的死亡情况（2017 年 7 月 1 日） 2002 年至 2022 年 6 月 30 日）。通过 4 个独立的数据库和搜索策略（国家大学体育协会决议清单、家长心脏观察数据库和媒体报道、国家灾难性运动损伤研究中心数据库和保险索赔）确定运动员死亡情况专家小组审查了尸检报告和病史，以判定 SCD 的原因。<b>结果：</b>从 1102 例死亡中，美国大学体育协会运动员中总共发现了 143 例 SCD 病例。美国大学体育协会决议清单确定了 143 例中的 117 例（ 82%），Parent Heart Watch 数据库或媒体报道确定了 143 起中的 89 起（62%），国家灾难性运动损伤研究中心数据库确定了 143 起中的 63 起（44%），保险索赔确定了 143 起中的 27 起（19%） ) SCD 病例。SCD 的总体发病率为 1:63682 运动员年 (95% CI, 1:54065-1:75010)。男性运动员的发病率高于女性运动员 (1:43348 [95% CI, 1 :36228-1:51867] 与 1:164504 [95% CI, 1:110552-1:244787] 运动员年，分别）以及黑人运动员与白人运动员的比较（1:26704 [1:20417-1:34925]分别为 1:74581 [1:60247-1:92326] 运动员年）。SCD 发病率最高的是一级男子篮球运动员（1:8188 [白人，1:5848；黑人，1:7696 运动员-年）。研究期间，SCD 的发病率有所下降（5 年发病率比，0.71 [95% CI，0.61-0.82]），而非心血管死亡率保持稳定（5 年发病率比， 0.98 [95% CI, 0.94-1.04])。尸检阴性的不明原因猝死 (19.5%) 是最常见的尸检结果，其次是特发性左心室肥厚或可能的心肌病 (16.9%) 和肥厚性心肌病 (12.7%) ，在有足够信息进行裁决的病例中（143 例中的 118 例）。研究期间有 8 例死亡归因于心肌炎（2020 年 1 月 1 日至 2022 年 6 月 30 日期间有 1 例死亡），没有一例归因于 COVID-19 感染50% 的病例发生劳力性 SCD 事件。劳力性 SCD 在冠状动脉异常 (100%) 和致心律失常性心肌病 (83%) 患者中更为常见。<b>结论：</b>大学生运动员 SCD 的发生率有所下降。男性、黑人和篮球与较高的 SCD 发病率相关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37955565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37955565</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065908>10.1161/CIRCULATIONAHA.123.065908</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955565</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>布拉德利·J·佩特克</dc:creator><dc:creator>蒂莫西·W·丘吉尔</dc:creator><dc:creator>纳撒尼尔·莫尔森</dc:creator><dc:creator>斯蒂芬妮·克里瑟姆斯</dc:creator><dc:creator>亚伦·L·巴吉什</dc:creator><dc:creator>乔纳森·德雷兹纳</dc:creator><dc:creator>马内什·R·帕特尔</dc:creator><dc:creator>迈克尔·J·阿克曼</dc:creator><dc:creator>克里斯汀·L·库塞拉</dc:creator><dc:creator>大卫·M·西伯特</dc:creator><dc:creator>劳伦·萨勒诺</dc:creator><dc:creator>莫妮卡·齐格曼·萨克斯兰</dc:creator><dc:creator>伊尔凡·M·阿西夫</dc:creator><dc:creator>约瑟夫·J·马莱谢夫斯基</dc:creator><dc:creator>金伯利·G·哈蒙</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>美国大学体育协会运动员的心脏性猝死：一项为期 20 年的研究</dc:title><dc:identifier>下午:37955565</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.065908</dc:identifier></item><item><title>年轻运动员心源性猝死的风险降低</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955558/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 11 月 13 日。doi：10.1161/CIRCULATIONAHA.123.067243。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37955558/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37955558</a> | DOI： <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067243>10.1161 / CIRCULATIONAHA.123.067243</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37955558</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator>多梅尼科·科拉多</dc:creator><dc:creator>亚历山德罗·佐尔齐</dc:creator><dc:date>2023-11-13</dc:date><dc:source>循环</dc:source><dc:title>年轻运动员心源性猝死的风险降低</dc:title><dc:identifier>下午：37955558</dc:identifier><dc:identifier> doi:10.1161/循环AHA.123.067243</dc:identifier></item><item><title>细胞周期蛋白 D-CDK4 二硫键减弱肺血管细胞增殖</title><link/>https://pubmed.ncbi.nlm.nih.gov/37955182/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231113193811&amp;v=2.17.9.post6+86293ac<description>结论：细胞周期蛋白D-CDK4中的一个新型二硫键充当快速开关，抑制激酶活性并阻止细胞增殖。这种氧化修饰形成于关键的半胱氨酸残基，这是CDK4所独有的，为设计预计对 PH 有益的选择性共价抑制剂。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 11 月 13 日。doi：10.1161/CIRCRESAHA.122.321836。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：肺动脉高压（PH）是一种慢性血管疾病，其特征包括平滑肌细胞过度增殖以及细胞氧化还原和代谢平衡紊乱。氧化剂诱导细胞周期停滞以停止增殖；然而，人们对氧化还原和代谢平衡知之甚少。在这里，我们报道了细胞周期蛋白 D-CDK4（细胞周期蛋白依赖性激酶 4）中的一种新型激酶抑制性二硫键，并研究了其在细胞增殖和 PH 中的作用。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在人肺动脉平滑肌细胞和人肺动脉内皮细胞中检测到细胞周期蛋白 D-CDK4 的氧化修饰。定点突变、串联质谱、基于细胞的实验、体外激酶活性测定、计算机结构模型，并利用一种新型氧化还原死亡组成型敲入小鼠来研究 CDK4 半胱氨酸修饰的性质并明确确定其在肺血管细胞增殖中的重要性。此外，在肺血管细胞中体内评估了细胞周期蛋白 D-CDK4 氧化。肺动脉高压患者和 3 个临床前 PH 模型中的动脉和分离的人肺动脉平滑肌细胞。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Cyclin D-CDK4 forms a reversible oxidant-induced heterodimeric disulfide dimer between C7/8 and C135, respectively, in cells in vitro and in pulmonary arteries in vivo to inhibit cyclin D-CDK4 kinase activity, decrease Rb (retinoblastoma) protein phosphorylation, and induce cell cycle arrest. Mutation of CDK4 C135 causes a kinase-impaired phenotype, which decreases cell proliferation rate and alleviates disease phenotype in an experimental mouse PH model, suggesting this cysteine is indispensable for cyclin D-CDK4 kinase activity. Pulmonary arteries and human pulmonary arterial smooth muscle cells from patients with pulmonary arterial hypertension display a decreased level of CDK4 disulfide, consistent with CDK4 being hyperactive in human pulmonary arterial hypertension. Furthermore, auranofin treatment, which induces the cyclin D-CDK4 disulfide, attenuates disease severity in experimental PH models by mitigating pulmonary vascular remodeling. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: A novel disulfide bond in cyclin D-CDK4 acts as a rapid switch to inhibit kinase activity and halt cell proliferation. This oxidative modification forms at a critical cysteine residue, which is unique to CDK4, offering the potential for the design of a selective covalent inhibitor predicted to be beneficial in PH.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955182/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37955182</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.122.321836>10.1161/CIRCRESAHA.122.321836</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955182</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Hannah Knight</dc:creator><dc:creator> Giancarlo Abis</dc:creator><dc:creator> Manpreet Kaur</dc:creator><dc:creator> Hannah LH Green</dc:creator><dc:creator> Susanne Krasemann</dc:creator><dc:creator> Kristin Hartmann</dc:creator><dc:creator> Steven Lynham</dc:creator><dc:creator> James Clark</dc:creator><dc:creator> Lan Zhao</dc:creator><dc:creator> Clemens Ruppert</dc:creator><dc:creator> Astrid Weiss</dc:creator><dc:creator> Ralph T Schermuly</dc:creator><dc:creator> Philip Eaton</dc:creator><dc:creator> Olena Rudyk</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation research</dc:source><dc:title> Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation</dc:title><dc:identifier> pmid:37955182</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.321836</dc:identifier></item><item><title> DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955153/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113193811&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Disorganized S/ER is a major characteristic of PLN-R14del cardiomyopathy in humans and mice and results in cardiomyocyte death. DWORF overexpression delayed PLN-R14del cardiomyopathy progression and extended life span in R14^(Δ/Δ) mice, by reducing abnormal S/ER clusters. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.123.323304. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: The p.Arg14del variant of the <i>PLN</i> (phospholamban) gene causes cardiomyopathy, leading to severe heart failure. Calcium handling defects and perinuclear PLN aggregation have both been suggested as pathological drivers of this disease. Dwarf open reading frame (DWORF) has been shown to counteract PLN regulatory calcium handling function in the sarco/endoplasmic reticulum (S/ER). Here, we investigated the potential disease-modulating action of DWORF in this cardiomyopathy and its effects on calcium handling and PLN aggregation. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: We studied a PLN-R14del mouse model, which develops cardiomyopathy with similar characteristics as human patients, and explored whether cardiac DWORF overexpression could delay cardiac deterioration. To this end, R14 <sup>Δ/Δ</sup> (homozygous PLN-R14del) mice carrying the DWORF transgene (R14 <sup>Δ/Δ</sup> DWORF <sup>Tg</sup> [R14 <sup>Δ/Δ</sup> mice with a copy of the DWORF transgene]) were used. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: DWORF expression was suppressed in hearts of R14 <sup>Δ/Δ</sup> mice with severe heart failure. Restoration of DWORF expression in R14 <sup>Δ/Δ</sup> mice delayed cardiac fibrosis and heart failure and increased life span >;2-fold (from 8 to 18 weeks). DWORF accelerated sarcoplasmic reticulum calcium reuptake and relaxation in isolated cardiomyocytes with wild-type PLN, but in R14 <sup>Δ/Δ</sup> cardiomyocytes, sarcoplasmic reticulum calcium reuptake and relaxation were already enhanced, and no differences were detected between R14 <sup>Δ/Δ</sup> and R14 <sup>Δ/Δ</sup> DWORF <sup>Tg</sup> . Rather, DWORF overexpression delayed the appearance and formation of large pathogenic perinuclear PLN clusters. Careful examination revealed colocalization of sarcoplasmic reticulum markers with these PLN clusters in both R14 <sup>Δ/Δ</sup> mice and human p.Arg14del PLN heart tissue, and hence these previously termed aggregates are comprised of abnormal organized S/ER. This abnormal S/ER organization in PLN-R14del cardiomyopathy contributes to cardiomyocyte cell loss and replacement fibrosis, consequently resulting in cardiac dysfunction. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Disorganized S/ER is a major characteristic of PLN-R14del cardiomyopathy in humans and mice and results in cardiomyocyte death. DWORF overexpression delayed PLN-R14del cardiomyopathy progression and extended life span in R14 <sup>Δ/Δ</sup> mice, by reducing abnormal S/ER clusters.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955153/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37955153</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.323304>10.1161/CIRCRESAHA.123.323304</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955153</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Nienke M Stege</dc:creator><dc:creator> Tim R Eijgenraam</dc:creator><dc:creator> Vivian Oliveira Nunes Teixeira</dc:creator><dc:creator> Anna M Feringa</dc:creator><dc:creator> Elisabeth M Schouten</dc:creator><dc:creator> Diederik WD Kuster</dc:creator><dc:creator> Jolanda van der Velden</dc:creator><dc:creator> Anouk HG Wolters</dc:creator><dc:creator> Ben NG Giepmans</dc:creator><dc:creator> Catherine A Makarewich</dc:creator><dc:creator> Rhonda Bassel-Duby</dc:creator><dc:creator> Eric N Olson</dc:creator><dc:creator> Rudolf A de Boer</dc:creator><dc:creator> Herman HW Silljé</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation research</dc:source><dc:title> DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters</dc:title><dc:identifier> pmid:37955153</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323304</dc:identifier></item><item><title> NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37955115/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113193811&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: Therefore, our data suggest that modulating epitranscriptomic processes, such as ac4C acetylation through NAT10, may be a promising therapeutic target against cardiac remodeling. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 Nov 13. doi: 10.1161/CIRCRESAHA.122.322244. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Heart failure, characterized by cardiac remodeling, is associated with abnormal epigenetic processes and aberrant gene expression. Here, we aimed to elucidate the effects and mechanisms of NAT10 (N-acetyltransferase 10)-mediated N4-acetylcytidine (ac4C) acetylation during cardiac remodeling. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: NAT10 and ac4C expression were detected in both human and mouse subjects with cardiac remodeling through multiple assays. Subsequently, acetylated RNA immunoprecipitation and sequencing, thiol (SH)-linked alkylation for the metabolic sequencing of RNA (SLAM-seq), and ribosome sequencing (Ribo-seq) were employed to elucidate the role of ac4C-modified posttranscriptional regulation in cardiac remodeling. Additionally, functional experiments involving the overexpression or knockdown of NAT10 were conducted in mice models challenged with Ang II (angiotensin II) and transverse aortic constriction. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: NAT10 expression and RNA ac4C levels were increased in in vitro and in vivo cardiac remodeling models, as well as in patients with cardiac hypertrophy. Silencing and inhibiting NAT10 attenuated Ang II-induced cardiomyocyte hypertrophy and cardiofibroblast activation. Next-generation sequencing revealed ac4C changes in both mice and humans with cardiac hypertrophy were associated with changes in global mRNA abundance, stability, and translation efficiency. Mechanistically, NAT10 could enhance the stability and translation efficiency of <i>CD47</i> and <i>ROCK2</i> transcripts by upregulating their mRNA ac4C modification, thereby resulting in an increase in their protein expression during cardiac remodeling. Furthermore, the administration of Remodelin, a NAT10 inhibitor, has been shown to prevent cardiac functional impairments in mice subjected to transverse aortic constriction by suppressing cardiac fibrosis, hypertrophy, and inflammatory responses, while also regulating the expression levels of CD47 and ROCK2. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Therefore, our data suggest that modulating epitranscriptomic processes, such as ac4C acetylation through NAT10, may be a promising therapeutic target against cardiac remodeling.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37955115/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37955115</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.122.322244>10.1161/CIRCRESAHA.122.322244</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37955115</guid><pubDate> Mon, 13 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Jing Shi</dc:creator><dc:creator> Chuanxi Yang</dc:creator><dc:creator> Kun Zhao</dc:creator><dc:creator> Jing Zhang</dc:creator><dc:creator> Peng Li</dc:creator><dc:creator> Chuiyu Kong</dc:creator><dc:creator> Xiaoguang Wu</dc:creator><dc:creator> Haoliang Sun</dc:creator><dc:creator> Rui Zheng</dc:creator><dc:creator> Wei Sun</dc:creator><dc:creator> Lianmin Chen</dc:creator><dc:creator> Xiangqing Kong</dc:creator><dc:date> 2023-11-13</dc:date><dc:source> Circulation research</dc:source><dc:title> NAT10 Is Involved in Cardiac Remodeling Through ac4C-Mediated Transcriptomic Regulation</dc:title><dc:identifier> pmid:37955115</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.122.322244</dc:identifier></item><item><title> Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria</title><link/> https://pubmed.ncbi.nlm.nih.gov/37952217/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113193811&amp;v=2.17.9.post6+86293ac<description> Background: Sodium glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone all individually reduce cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes and albuminuria. However, the lifetime benefits of combination therapy with these medicines are not known. Methods: We used data from 2 SGLT2i trials (CANVAS and CREDENCE), 2 non-steroidal MRA trials... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067584. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Sodium glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone all individually reduce cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes and albuminuria. However, the lifetime benefits of combination therapy with these medicines are not known. <b>Methods:</b> We used data from 2 SGLT2i trials (CANVAS and CREDENCE), 2 non-steroidal MRA trials (FIDELIO-DKD and FIGARO-DKD) and 8 GLP-1 RA trials to estimate the relative effects of combination therapy versus conventional care (renin-angiotensin system blockade and traditional risk factor control) on cardiovascular, kidney and mortality outcomes. Using actuarial methods, we then estimated absolute risk reductions with combination SGLT2i, GLP-1 RA and non-steroidal MRA in patients with type 2 diabetes and at lease moderately increased albuminuria (urinary albumin:creatinine ratio ≥30 mg/g) by applying estimated combination treatment effects to participants receiving conventional care in CANVAS and CREDENCE. <b>Results:</b> Compared to conventional care, combination SGLT2i, GLP-1 RA and non-steroidal MRA was associated with a hazard ratio of 0.65 (95% CI 0.55-0.76) for major adverse cardiovascular events (MACE; nonfatal myocardial infarction, nonfatal stroke or cardiovascular death). The corresponding estimated absolute risk reduction over 3 years was 4.4% (95% CI 3.0-5.7) with a number-needed-to-treat of 23 (95% CI 18-33). For a 50-year-old commencing combination therapy, estimated MACE event-free survival was 21.1 years compared to 17.9 years for conventional care (3.2 years gained, 95% CI 2.1-4.3). There were also projected gains in survival free from hospitalized heart failure (3.2 years, 95% CI 2.4-4.0), CKD progression (5.5 years, 95% CI 4.0-6.7), cardiovascular death (2.2 years, 95% CI 1.2-3.0) and all-cause death (2.4 years, 95% CI 1.4-3.4). Attenuated but clinically relevant gains in event-free survival were observed in analyses assuming 50% additive effects of combination therapy, including for MACE (2.4 years, 95% CI 1.1-3.5), CKD progression (4.5 years, 95% CI 2.8-5.9),) and all-cause death (1.8 years, 95% CI 0.7-2.8). <b>Conclusions:</b> In patients with type 2 diabetes and at least moderately increased albuminuria, combination treatment with SGLT2i, GLP-1 RA and non-steroidal MRA has the potential to afford relevant gains in cardiovascular and kidney event-free and overall survival.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37952217/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37952217</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067584>10.1161/CIRCULATIONAHA.123.067584</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37952217</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Brendon L Neuen</dc:creator><dc:creator> Hiddo JL Heerspink</dc:creator><dc:creator> Priya Vart</dc:creator><dc:creator> Brian L Claggett</dc:creator><dc:creator> Robert A Fletcher</dc:creator><dc:creator> Clare Arnott</dc:creator><dc:creator> Juliana de Oliveira Costa</dc:creator><dc:creator> Michael O Falster</dc:creator><dc:creator> Sallie-Anne Pearson</dc:creator><dc:creator> Kenneth W Mahaffey</dc:creator><dc:creator> Bruce Neal</dc:creator><dc:creator> Rajiv Agarwal</dc:creator><dc:creator> George Bakris</dc:creator><dc:creator> Vlado Perkovic</dc:creator><dc:creator> Scott D Solomon</dc:creator><dc:creator> Muthiah Vaduganathan</dc:creator><dc:date> 2023-11-12</dc:date><dc:source> Circulation</dc:source><dc:title> Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria</dc:title><dc:identifier> pmid:37952217</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.067584</dc:identifier></item><item><title> Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias</title><link/> https://pubmed.ncbi.nlm.nih.gov/37952204/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113193811&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: CHIP may represent a novel risk factor for incident arrhythmias, indicating a potential target for modulation towards arrhythmia prevention and treatment. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Nov 11:ehad670. doi: 10.1093/eurheartj/ehad670. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Clonal haematopoiesis of indeterminate potential (CHIP), the age-related expansion of blood cells with preleukemic mutations, is associated with atherosclerotic cardiovascular disease and heart failure. This study aimed to test the association of CHIP with new-onset arrhythmias. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: UK Biobank participants without prevalent arrhythmias were included. Co-primary study outcomes were supraventricular arrhythmias, bradyarrhythmias, and ventricular arrhythmias. Secondary outcomes were cardiac arrest, atrial fibrillation, and any arrhythmia. Associations of any CHIP [variant allele fraction (VAF) ≥ 2%], large CHIP (VAF ≥10%), and gene-specific CHIP subtypes with incident arrhythmias were evaluated using multivariable-adjusted Cox regression. Associations of CHIP with myocardial interstitial fibrosis [T1 measured using cardiac magnetic resonance (CMR)] were also tested. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: This study included 410 702 participants [CHIP: n = 13 892 (3.4%); large CHIP: n = 9191 (2.2%)]. Any and large CHIP were associated with multi-variable-adjusted hazard ratios of 1.11 [95% confidence interval (CI) 1.04-1.18; P = .001] and 1.13 (95% CI 1.05-1.22; P = .001) for supraventricular arrhythmias, 1.09 (95% CI 1.01-1.19; P = .031) and 1.13 (95% CI 1.03-1.25; P = .011) for bradyarrhythmias, and 1.16 (95% CI, 1.00-1.34; P = .049) and 1.22 (95% CI 1.03-1.45; P = .021) for ventricular arrhythmias, respectively. Associations were independent of coronary artery disease and heart failure. Associations were also heterogeneous across arrhythmia subtypes and strongest for cardiac arrest. Gene-specific analyses revealed an increased risk of arrhythmias across driver genes other than DNMT3A. Large CHIP was associated with 1.31-fold odds (95% CI 1.07-1.59; P = .009) of being in the top quintile of myocardial fibrosis by CMR. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: CHIP may represent a novel risk factor for incident arrhythmias, indicating a potential target for modulation towards arrhythmia prevention and treatment.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37952204/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37952204</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad670>10.1093/eurheartj/ehad670</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37952204</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Art Schuermans</dc:creator><dc:creator> Caitlyn Vlasschaert</dc:creator><dc:creator> Victor Nauffal</dc:creator><dc:creator> So Mi Jemma Cho</dc:creator><dc:creator> Md Mesbah Uddin</dc:creator><dc:creator> Tetsushi Nakao</dc:creator><dc:creator> Abhishek Niroula</dc:creator><dc:creator> Marcus DR Klarqvist</dc:creator><dc:creator> Lachelle D Weeks</dc:creator><dc:creator> Amy E Lin</dc:creator><dc:creator> Seyedmohammad Saadatagah</dc:creator><dc:creator> Kim Lannery</dc:creator><dc:creator> Megan Wong</dc:creator><dc:creator> Whitney Hornsby</dc:creator><dc:creator> Steven A Lubitz</dc:creator><dc:creator> Christie Ballantyne</dc:creator><dc:creator> Siddhartha Jaiswal</dc:creator><dc:creator> Peter Libby</dc:creator><dc:creator> Benjamin L Ebert</dc:creator><dc:creator> Alexander G Bick</dc:creator><dc:creator> Patrick T Ellinor</dc:creator><dc:creator> Pradeep Natarajan</dc:creator><dc:creator> Michael C Honigberg</dc:creator><dc:date> 2023-11-12</dc:date><dc:source> European heart journal</dc:source><dc:title> Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmias</dc:title><dc:identifier> pmid:37952204</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad670</dc:identifier></item><item><title> Bag-Valve-Mask Ventilation and Survival from Out-of-Hospital Cardiac Arrest: A Multicenter Study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37952192/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231113193811&amp;v=2.17.9.post6+86293ac<description> Background: Few studies have measured ventilation during early cardiopulmonary resuscitation (CPR) before advanced airway placement. Resuscitation guidelines recommend pauses after every 30 chest compressions to deliver ventilations. The effectiveness of bag-valve-mask ventilation delivered during the pause in chest compressions is unknown. We sought to determine: (1) the incidence of lung inflation with bag-valve-mask ventilation during 30:2 CPR; and (2) the association of ventilation with... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.065561. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> <b>Background:</b> Few studies have measured ventilation during early cardiopulmonary resuscitation (CPR) before advanced airway placement. Resuscitation guidelines recommend pauses after every 30 chest compressions to deliver ventilations. The effectiveness of bag-valve-mask ventilation delivered during the pause in chest compressions is unknown. We sought to determine: (1) the incidence of lung inflation with bag-valve-mask ventilation during 30:2 CPR; and (2) the association of ventilation with outcomes after out-of-hospital cardiac arrest. <b>Methods:</b> We studied patients with out-of-hospital cardiac arrest from 6 sites of the Resuscitation Outcomes Consortium CCC study (Trial of Continuous Compressions versus Standard CPR in Patients with Out-of-Hospital Cardiac Arrest). We analyzed patients assigned to the 30:2 CPR arm with ≥2 minutes of thoracic bioimpedance signal recorded with a cardiac defibrillator/monitor. Detectable ventilation waveforms were defined as having a bioimpedance amplitude ≥0.5 Ω (corresponding to ≥250 mL V <sub>T</sub> ) and a duration ≥1 s. We defined a chest compression pause as a 3- to 15-s break in chest compressions. We compared the incidence of ventilation and outcomes in 2 groups: patients with ventilation waveforms in &lt;50% of pauses (group 1) versus those with waveforms in ≥50% of pauses (group 2). <b>Results:</b> Among 1976 patients, the mean age was 65 years; 66% were male. From the start of chest compressions until advanced airway placement, mean±SD duration of 30:2 CPR was 9.8±4.9 minutes. During this period, we identified 26861 pauses in chest compressions; 60% of patients had ventilation waveforms in &lt;50% of pauses (group 1, n=1177), and 40% had waveforms in ≥50% of pauses (group 2, n=799). Group 1 had a median of 12 pauses and 2 ventilations per patient versus group 2, which had 12 pauses and 12 ventilations per patient. Group 2 had higher rates of prehospital return of spontaneous circulation (40.7% versus 25.2%; <i>P</i> &lt;0.0001), survival to hospital discharge (13.5% versus 4.1%; <i>P</i> &lt;0.0001), and survival with favorable neurological outcome (10.6% versus 2.4%; <i>P</i> &lt;0.0001). These associations persisted after adjustment for confounders. <b>Conclusions:</b> In this study, lung inflation occurred infrequently with bag-valve-mask ventilation during 30:2 CPR. Lung inflation in ≥50% of pauses was associated with improved return of spontaneous circulation, survival, and survival with favorable neurological outcome.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37952192/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231113193811&v=2.17.9.post6+86293ac">37952192</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065561>10.1161/CIRCULATIONAHA.123.065561</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37952192</guid><pubDate> Sun, 12 Nov 2023 06:00:00 -0500</pubDate><dc:creator> Ahamed H Idris</dc:creator><dc:creator> Elisabete Aramendi Ecenarro</dc:creator><dc:creator> Brian Leroux</dc:creator><dc:creator> Xabier Jaureguibeitia</dc:creator><dc:creator> Betty Y Yang</dc:creator><dc:creator> Sarah Shaver</dc:creator><dc:creator> Mary P Chang</dc:creator><dc:creator> Tom Rea</dc:creator><dc:creator> Peter Kudenchuk</dc:creator><dc:creator> Jim Christenson</dc:creator><dc:creator> Christian Vaillancourt</dc:creator><dc:creator> Clifton W Callaway</dc:creator><dc:creator> David Salcido</dc:creator><dc:creator> Jonas Carson</dc:creator><dc:creator> Jennifer Blackwood</dc:creator><dc:creator> Henry E Wang</dc:creator><dc:date> 2023-11-12</dc:date><dc:source> Circulation</dc:source><dc:title> Bag-Valve-Mask Ventilation and Survival from Out-of-Hospital Cardiac Arrest: A Multicenter Study</dc:title><dc:identifier> pmid:37952192</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065561</dc:identifier></item></channel></rss>